Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMN 673 · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | Period 1: fasted control → Period 2: fed control |
| Treatment B | EXPERIMENTAL | Period 1: fed control → Period 2: fasted control |
| Arm 1: BMN 673 | EXPERIMENTAL | Arm 1 will enroll patients with either AML or MDS |
| Arm 2: BMN 673 | EXPERIMENTAL | Arm 2 will enroll patients with either CLL or MCL |
| Name | Type | Description |
|---|---|---|
| BMN 673 | DRUG | 500mcg dose of BMN 673, 2 discrete single doses separated by 21 days |
Inclusion Criteria: * Male, between the ages of 18 and 55. * Non-smoking for at least 1 year before Screening. * Willing and able to provide informed consent. * Have a BMI between 18 to 30kg/m2. * Willing and able to comply all study procedures. * Have adequate organ function * Sexually active pati...
BMN 673 is a small molecule being studied for use in Acute Myeloid Leukemia and other advanced hematological malignancies, as well as in healthy human volunteers. It is an investigational drug in Phase 1 clinical development and is not yet approved for any indication.
BMN 673 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with certain blood cancers and in healthy volunteers.
BMN 673 is in Phase 1 clinical development. It has completed two Phase 1 trials, one in patients with advanced hematological malignancies and one in healthy adult male volunteers. The drug remains investigational and has not received FDA approval.
BMN 673 has been studied in two completed Phase 1 trials. NCT01399840 enrolled 33 patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, and Mantle Cell Lymphoma. NCT01776437 enrolled 18 healthy adult male volunteers. Both trials were conducted in the United States, with the first also in the United Kingdom.
BMN 673 is also known as talazoparib, a PARP inhibitor. In clinical trials, it has been evaluated for its effects in patients with advanced hematological malignancies and in healthy volunteers. The drug is being developed by Pfizer, Inc.